Switzerland· 54630002
Simulect 10 mg, Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung
A basiliximab product, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category B. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Basiliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC02 (basiliximab), each read from that country’s own register.
- This record: Switzerland
- 9 of them publish a price we can compare per daily dose
Basiliximab · ATC L04AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Manufacturer
- Novartis Pharma Schweiz AG
- Country
- Switzerland (CH)
- ATC code
- L04AC02
- ATC class
- Basiliximab
- Defined daily dose
- 40 mg, P
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for basiliximab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Basiliximab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AC02
Basiliximab, as other registers publish it.
- FinlandSimulectNovartis Europharm Limited
- PolandSimulectNovartis Europharm Limited
- NorwaySimulectNovartis Europharm Limited (1)
- FinlandSimulectNovartis Europharm Limited
- FinlandSimulectNovartis Europharm Limited
- PolandSimulectNovartis Europharm Limited
- FinlandSimulect2care4 ApS
- IcelandSimulectNovartis Europharm Limited*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae2ed9a0-2ca1-4dae-ba1b-84596709a7a5 GET /v1/drugs/ae2ed9a0-2ca1-4dae-ba1b-84596709a7a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about basiliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.